ADMA - ADMA Biologics, Inc.
2.9820 +0.04 (1.43%)
After hours: 4:48PM EDT
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.8400 |
| Open | 2.9300 |
| Bid | 2.9200 x 2900 |
| Ask | 2.9900 x 2900 |
| Day's Range | 2.8750 - 3.1150 |
| 52 Week Range | 1.4500 - 5.4840 |
| Volume | 4,459,194 |
| Avg. Volume | 2,945,391 |
| Market Cap | 253.855M |
| Beta (5Y Monthly) | 2.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8900 |
| Earnings Date | May 06, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
Fair Value
Related Research
- GlobeNewswire
ADMA Biologics Commences Collection of COVID-19 Plasma from Recovered Patients
ADMA is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA is seeking US citizens who have recovered from coronavirus (SARS-CoV-2) or COVID-19, to donate plasma, which can be used to produce an immune globulin to potentially help infected patients with COVID-19.
- Motley Fool
ADMA Biologics Inc (ADMA) Q1 2020 Earnings Call Transcript
At this time, I would like to introduce Mr. Sam Martin, Managing Director at Argot Partners, ADMA's Investor Relations firm. Welcome everyone, and thank you for joining us this afternoon to discuss ADMA Biologics' financial results for the first quarter 2020.
- Thomson Reuters StreetEvents
Edited Transcript of ADMA earnings conference call or presentation 6-May-20 8:30pm GMT
Q1 2020 ADMA Biologics Inc Earnings Call
- PR Newswire
CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration
The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19, is rapidly building momentum. Its membership has expanded globally to include 10 plasma companies, and now also includes global organizations from outside the plasma industry who are providing vital support to encourage more people to donate plasma.
- GlobeNewswire
ADMA Biologics Provides Corporate Update on Supply Chain Robustness and Recent Accomplishments
RAMSEY, N.J. and BOCA RATON, Fla., May 07, 2020 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,.
- Zacks
Adma Biologics (ADMA) Reports Q1 Loss, Misses Revenue Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of -100.00% and -4.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
ADMA Biologics Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress
Achieved First Quarter 2020 Total Revenues of $10.2 Million, a 189% Increase Over First Quarter 2019 Strengthened Balance Sheet Through Successful Completion of Underwritten.
- Simply Wall St.
Investors Who Bought ADMA Biologics (NASDAQ:ADMA) Shares Five Years Ago Are Now Down 60%
Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...
- GlobeNewswire
ADMA Biologics to Report First Quarter 2020 Financial Results on May 6, 2020
ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.
- Thomson Reuters StreetEvents
Edited Transcript of ADMA earnings conference call or presentation 12-Mar-20 8:30pm GMT
Q4 2019 ADMA Biologics Inc Earnings Call
- Simply Wall St.
US$11.00: That's What Analysts Think ADMA Biologics, Inc. Is Worth After Its Latest Results
One of the biggest stories of last week was how ADMA Biologics, Inc. (NASDAQ:ADMA) shares plunged 30% in the week...
- GlobeNewswire
ADMA Biologics Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
Achieved Fourth Quarter 2019 Total Revenues of $12.0 Million, a 197% Increase Over Fourth Quarter 2018 Achieved Full Year 2019 Total Revenues of $29.3 Million, a 73% Increase.
- ACCESSWIRE
ADMA Biologics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / ADMA Biologics, Inc. (NASDAQ:ADMA) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 4:30 ...
- GlobeNewswire
ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2020 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to.
- GlobeNewswire
ADMA Biologics Highlights Expanded Intellectual Property Portfolio for Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections
ADMA Biologics (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases, today announced that it has received another Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its intellectual property portfolio encompassing immunoglobulin plasma pool compositions used in the manufacturing of ASCENIV™. ADMA is the exclusive owner of intellectual property encompassing certain immunotherapeutic, immunoglobulin (IG & IVIG) compositions for the prevention and treatment of a wide variety of respiratory infections, including certain strains of coronavirus.
- GlobeNewswire
ADMA Biologics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock
The shares were issued pursuant to the full exercise of the underwriters’ overallotment option in connection with ADMA’s previously announced underwritten public offering of 23,500,000 shares of its common stock. The gross proceeds from the exercise of the overallotment option were approximately $12.3 million, bringing the total gross proceeds to ADMA from the offering to approximately $94.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
- Simply Wall St.
Adam Grossman Is The Co-Founder of ADMA Biologics, Inc. (NASDAQ:ADMA) And They Just Spent US$300k On Shares
Investors who take an interest in ADMA Biologics, Inc. (NASDAQ:ADMA) should definitely note that the Co-Founder, Adam...
- GlobeNewswire
ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 11, 2020 -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,.
- Benzinga
The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
- GlobeNewswire
ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock
The offering is expected to close on February 11, 2020, subject to the satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to 3,525,000 additional shares of common stock at the public offering price less the underwriting discount.
- GlobeNewswire
ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock
The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- Simply Wall St.
When Will ADMA Biologics, Inc. (NASDAQ:ADMA) Become Profitable?
ADMA Biologics, Inc.'s (NASDAQ:ADMA): ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company...
- GlobeNewswire
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook
ADMA Biologics, Inc. (ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the prevention of certain infectious diseases, today announced its preliminary unaudited fourth quarter and full year 2019 revenues.
- GlobeNewswire
ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions
ADMA Biologics, Inc. (ADMA), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the prevention of certain infectious diseases, today announced its entry into a 5-year manufacturing and supply agreement with an undisclosed partner to produce and sell plasma-derived intermediate fractions from ADMA’s U.S. Food and Drug Administration (FDA) approved Immune Globulin (IG) manufacturing process.
- Simply Wall St.
Have Insiders Been Buying ADMA Biologics, Inc. (NASDAQ:ADMA) Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
